Labradimil is a bradykinin B2 receptor agonist. Labradimil increases the permeability of human brain microvascular endothelial cell monolayers. Labradimil enhances delivery of hydrophilic chemotherapeutics and increases survival in rats with metastatic tumors in the brain. Labradimil increases carboplatin levels in brain tumors after pretreatment with dexamethasone.

159768-75-9

C49H75N15O12S

1098.28

DRG 0182;RMP-7;Receptor-mediated permeabiliser-7;ALK-01-040;DRG0182;DRG-0182;Labradimil

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years